ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026

ConferenceITM-11Ga-DPI-4452Neutral

AI Analysis

Summary

ITM Isotope Technologies Munich SE and Lumara Bio announced that Phase 3 COMPETE trial dose-response data for 177Lu-edotreotide and interim imaging results for Ga-DPI-4452 will be presented at the EANM Congress in Vienna on October 17-21, 2026.

Clinical Trial Data

Phase

Phase 3

NCT ID

NCT0304918

Outcome Details

Phase 3 COMPETE trial dose-response findings and interim imaging analysis results to be presented at EANM 2026

Importance:5/10

Sentiment:

0.00

radiopharmaceuticalneuroendocrine tumorsrenal cell carcinomaPET/CT imagingconference presentationPhase 3 data

Related Companies

$GBIO $MOLN $DFPH $SHWZ $MDCE $SURF $GBCMD

Read the original article

Published by GlobeNewswire Clinical Studies on October 7, 2026 9:00 AM

Read Original